Cortexyme Stock News

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns whether Cortexyme has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 26, 2021, Cortexyme issued a press release “report[ing

Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in re

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CRTX #CRTX--The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/crtx .

The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana

Cortexyme (CRTX) provided a business update and announced key milestones for 2022

Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB,

The FDA''s latest move regarding one of this biopharma''s investigational drugs all but slams the door shut on its future.

Cortexyme Inc  (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug f

The FDA has placed a clinical hold on Cortexyme Inc''s (NASDAQ: CRTX ) atuzaginstat (COR388) Investigational New Drug application (IND 134303). The Company plans to provide additional updates pending continued engagement with FDA. Cortexyme is immediately implementing a cost reduction program to rationalize operations, providing an expected cash runway through Full story available on Benzinga.com

Cortexyme (CRTX) drops 33.9% premarket after receiving a letter from the FDA, stating the the Agency is placing a full clinical hold on company''s atuzaginstats (COR388)